Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04976322 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

StatusEnrolling by Invitation
PhasePhase 3
Started2021-07-27
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 103 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

2026-09-03
Study Status, Contacts/Locations v102
Study sites119→120
2026-08-20
Study Status, Contacts/Locations v101
Study sites121→119
2026-08-06
Study Status, Contacts/Locations v100
Trial sites expanded: 118 → 121 locations
2026-07-23
Study Status, Contacts/Locations v99
Trial sites expanded: 113 → 118 locations
2026-07-09
Study Status, Contacts/Locations v98
Study sites115→113
2026-06-25
Study Status, Contacts/Locations v97
Study sitesdetails revised at 1 of 115 sites
2026-06-11
Study Status, Contacts/Locations v96
Trial sites expanded: 109 → 115 locations
2026-05-28
Study Status, Contacts/Locations v95
Trial sites expanded: 106 → 109 locations
2026-05-14
Study Status, Contacts/Locations v94
Study sites106 entries, revised
Sl0046 2003150671
2026-04-30
Study Status, Contacts/Locations v93
Study sites104→106
2026-04-16
Study Status, Contacts/Locations v92
Study sites102→104
2026-04-02
Study Status, Contacts/Locations v91
Trial sites reduced: 105 → 102 locations
2026-03-19
Study Status, Contacts/Locations v90
Study sites102→105
2026-03-05
Study Status, Contacts/Locations v89
Study sites98→102
2026-02-05
5 amendments v84-v88
5 re-verifications since 2025-12-11, no change to tracked fields
2025-11-27
Study Status, Contacts/Locations v83
Study sitesdetails revised at 1 of 98 sites
2025-10-30
Study Status, Contacts/Locations v82
Study sites97→98
2025-10-01
2 amendments v80-v81
2 re-verifications since 2025-09-04, no change to tracked fields
2025-08-26
Study Status v79
Primary completion date2029-04-10→2030-08-07
Completion date2029-04-10→2030-08-07
2025-08-07
Study Status, Contacts/Locations v78
Study sitesdetails revised at 1 of 97 sites
2025-07-24
6 amendments v72-v77
6 re-verifications since 2025-05-01, no change to tracked fields
2025-04-17
Study Status, Contacts/Locations v71
Study sitesdetails revised at 1 of 97 sites
2025-02-11
3 amendments v68-v70
3 re-verifications since 2025-01-09, no change to tracked fields
2024-12-03
Study Identification, Study Status, Outcome Measures, Eligibility v67
Eligibility criteria-36 characters
[...] b pegol (DZP) treatment The participant completed one of the placebo controlled (PBO-controlled) parent studies within 4 weeks prior to entry to this study [...]
2024-11-14
Study Status, Contacts/Locations v66
Study sitesdetails revised at 1 of 97 sites
2024-10-29
Study Status v65
Re-verified, no change to tracked fields
2024-10-17
Study Status, Contacts/Locations v64
Study sitesdetails revised at 1 of 97 sites
2024-09-19
4 amendments v60-v63
4 re-verifications since 2024-07-11, no change to tracked fields
2024-05-30
Study Status, Contacts/Locations v59
Study sites95→97
2024-05-16
Study Status, Contacts/Locations v58
Study sites94→95
2024-05-02
Study Status, Contacts/Locations v57
Study sites88→94
2024-02-22
3 amendments v54-v56
3 re-verifications since 2024-01-26, no change to tracked fields
2024-01-25
Study Status, Contacts/Locations v53
Study sites86→88
UCB Biopharma SRL
68 trials monitored
See 4 trials at risk
Lupus (SLE)
648 trials monitored
See 25 trials at risk
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
Trial Details
NCT Number NCT04976322
Lead Sponsor UCB Biopharma SRL
Conditions Systemic Lupus Erythematosus
Enrollment 760 participants
Start Date 2021-07-27
Primary Completion 2030-08-07 (estimated)
Study Completion 2030-08-07 (estimated)
Updated on ClinicalTrials.gov 2026-09-18